# Mikhail N Kosiborod

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 265 papers | 17,917 citations | 62 h-index | 129 g-index |
| 322 ext. papers | 24,099 ext. citations | 9.7 avg, IF | 6.6 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 265 | Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study.. *Diabetes Research and Clinical Practice*, **2022**, 185, 109218 | 7.4 | 0 |
| 264 | Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. *American Heart Journal*, **2022**, 243, 232-239 | 4.9 | 4 |
| 263 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.. *Nature Medicine*, **2022**, | 50.5 | 27 |
| 262 | Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. *Cardiovascular Diabetology*, **2022**, 21, 50 | 8.7 | 1 |
| 261 | 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.. *Diabetes Care*, **2022**, 45, S83-S96 | 14.6 | 39 |
| 260 | Dapagliflozin in patients with COVID-19: mind the kidneys - AuthorsOreply.. *Lancet Diabetes and Endocrinology,the*, **2021**, | 18.1 | |
| 259 | Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. *Circulation*, **2021**, | 16.7 | 1 |
| 258 | Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes and Endocrinology,the* , **2021**, | 18.1 | 3 |
| 257 | Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. *Diabetes Care*, **2021**, 44, 586-594 | 14.6 | 24 |
| 256 | Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. *Circulation: Heart Failure*, **2021**, 14, e008446 | 7.6 | 1 |
| 255 | Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. *Journal of Diabetes and Its Complications*, **2021**, 35, 108077 | 3.2 | 0 |
| 254 | The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nature Medicine*, **2021**, 27, 1954-1960 | 50.5 | 29 |
| 253 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. *European Heart Journal*, **2021**, | 9.5 | 17 |
| 252 | Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. *European Journal of Heart Failure*, **2021**, 23, 826-834 | 12.3 | 23 |
| 251 | Effect of dapagliflozin on anaemia in DAPA-HF. *European Journal of Heart Failure*, **2021**, 23, 617-628 | 12.3 | 14 |
| 250 | Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1431-1435 | 6.7 | 4 |
| 249 | Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. *European Heart Journal*, **2021**, 42, 1216-1227 | 9.5 | 25 |

| | | | |
|---|---|---|---|
| 248 | Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1426-1430 | 6.7 | 5 |
| 247 | Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. *European Journal of Heart Failure*, **2021**, 23, 601-613 | 12.3 | 14 |
| 246 | Methods and rationale of the DISCOVER CKD global observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1570-1578 | 4.5 | 1 |
| 245 | Long COVID - metabolic risk factors and novel therapeutic management. *Nature Reviews Endocrinology*, **2021**, 17, 379-380 | 15.2 | 11 |
| 244 | Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. *Circulation*, **2021**, 143, 1673-1686 | 16.7 | 35 |
| 243 | Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. *JACC: Heart Failure*, **2021**, 9, 254-264 | 7.9 | 23 |
| 242 | Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. *European Journal of Heart Failure*, **2021**, 23, 1085-1093 | 12.3 | 9 |
| 241 | Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. *Circulation*, **2021**, 143, 1962-1972 | 16.7 | 13 |
| 240 | Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. *Journal of the American College of Cardiology*, **2021**, 77, 2366-2377 | 15.1 | 2 |
| 239 | Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. *JAMA Cardiology*, **2021**, 6, 499-507 | 16.2 | 35 |
| 238 | Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1956-1960 | 6.7 | 2 |
| 237 | Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 1499-1505 | 14.6 | 4 |
| 236 | Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *European Journal of Heart Failure*, **2021**, 23, 1217-1225 | 12.3 | 39 |
| 235 | Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. *ESC Heart Failure*, **2021**, 8, 2603-2607 | 3.7 | 4 |
| 234 | Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence. *Journal of Heart and Lung Transplantation*, **2021**, 40, 426-429 | 5.8 | 1 |
| 233 | Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. *JAMA Cardiology*, **2021**, 6, 678-689 | 16.2 | 7 |
| 232 | Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. *Cardiovascular Diabetology*, **2021**, 20, 159 | 8.7 | 3 |
| 231 | Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. *JAMA Cardiology*, **2021**, 6, 1298-1305 | 16.2 | 2 |

| | | | |
|---|---|---|---|
| 230 | Sodium-glucose cotransporter‐2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. *Journal of Diabetes Investigation*, **2021**, 12, 67-73 | 3.9 | 2 |
| 229 | Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. *Nephrology Dialysis Transplantation*, **2021**, 36, 137-150 | 4.3 | 14 |
| 228 | Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. *Circulation*, **2021**, 143, 298-309 | 16.7 | 69 |
| 227 | Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *New England Journal of Medicine*, **2021**, 384, 129-139 | 59.2 | 243 |
| 226 | Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 886-896 | 6.7 | 19 |
| 225 | Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). *Diabetes, Obesity and Metabolism*, **2021**, 23, 455-466 | 6.7 | 4 |
| 224 | Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 39-48 | 6.7 | 4 |
| 223 | Type 2 diabetes and heart failure: insights from the global DISCOVER study. *ESC Heart Failure*, **2021**, 8, 1711-1716 | 3.7 | 6 |
| 222 | Novel Trial Design: CHIEF-HF. *Circulation: Heart Failure*, **2021**, 14, e007767 | 7.6 | 1 |
| 221 | Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. *European Journal of Heart Failure*, **2021**, 23, 1662-1672 | 12.3 | 6 |
| 220 | Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. *Cardiovascular Diabetology*, **2021**, 20, 139 | 8.7 | 2 |
| 219 | Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. *Diabetes Research and Clinical Practice*, **2021**, 177, 108870 | 7.4 | 1 |
| 218 | Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease. *Clinical Cardiology*, **2021**, 44, 1457-1466 | 3.3 | 2 |
| 217 | Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. *European Heart Journal*, **2021**, 42, 3727-3738 | 9.5 | 22 |
| 216 | What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. *Journal of the American Heart Association*, **2021**, 10, e020893 | 6 | 0 |
| 215 | Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 586-594 | 18.1 | 38 |
| 214 | A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. *IScience*, **2021**, 24, 103040 | 6.1 | 6 |
| 213 | Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes. *Circulation: Cardiovascular Quality and Outcomes*, **2021**, 14, e007682 | 5.8 | 2 |

| | | | |
|---|---|---|---|
| 212 | A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. *Kidney International*, **2021**, | 9.9 | 9 |
| 211 | Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. *Diabetes Research and Clinical Practice*, **2021**, 180, 108974 | 7.4 | 1 |
| 210 | Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. *Circulation: Heart Failure*, **2020**, 13, e007879 | 7.6 | 7 |
| 209 | Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. *European Journal of Heart Failure*, **2020**, 22, 1247-1258 | 12.3 | 19 |
| 208 | Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry. *Journal of Diabetes and Its Complications*, **2020**, 34, 107591 | 3.2 | 3 |
| 207 | Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. *Diabetes Research and Clinical Practice*, **2020**, 165, 108250 | 7.4 | 3 |
| 206 | The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. *International Journal of Cardiology*, **2020**, 318, 126-129 | 3.2 | 6 |
| 205 | Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. *Cardiovascular Endocrinology and Metabolism*, **2020**, 9, 56-59 | 2.5 | 7 |
| 204 | Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2836-2850 | 15.1 | 36 |
| 203 | Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 606-615 | 18.1 | 37 |
| 202 | Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. *JAMA - Journal of the American Medical Association*, **2020**, 323, 1353-1368 | 27.4 | 155 |
| 201 | Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. *European Heart Journal*, **2020**, 41, 2379-2392 | 9.5 | 80 |
| 200 | RESPONSE: The Imperative to Change the Delivery of Cardiometabolic Care: The Future Is Now. *Journal of the American College of Cardiology*, **2020**, 75, 1236-1237 | 15.1 | |
| 199 | Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. *Diabetes Care*, **2020**, 43, 867-874 | 14.6 | 26 |
| 198 | Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. *American Heart Journal*, **2020**, 219, 70-77 | 4.9 | 9 |
| 197 | Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. *Diabetes, Obesity and Metabolism*, **2020**, 22, 66-78 | 6.7 | 8 |
| 196 | Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. *Circulation*, **2020**, 141, 100-111 | 16.7 | 68 |
| 195 | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. *Circulation*, **2020**, 141, 90-99 | 16.7 | 130 |

| | | | |
|---|---|---|---|
| 194 | Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 27-35 | 18.1 | 109 |
| 193 | Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. *American Journal of Nephrology*, **2020**, 51, 74-82 | 4.6 | 11 |
| 192 | Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. *Circulation*, **2020**, 142, 1040-1054 | 16.7 | 52 |
| 191 | Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. *Diabetes Care*, **2020**, 43, 1958-1966 | 14.6 | 9 |
| 190 | Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes. *Endocrinology, Diabetes and Metabolism*, **2020**, 3, e00126 | 2.7 | 1 |
| 189 | Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial. *Journal of Cardiac Failure*, **2020**, 26, 1109-1110 | 3.3 | |
| 188 | 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, **2020**, 76, 1117-1145 | 15.1 | 124 |
| 187 | Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2364-2374 | 6.7 | 11 |
| 186 | Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. *Current Opinion in Cardiology*, **2020**, 35, 589-601 | 2.1 | |
| 185 | Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. *BMJ Open*, **2020**, 10, e034613 | 3 | 0 |
| 184 | Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. *Diabetes Care*, **2020**, 43, 2878-2881 | 14.6 | 8 |
| 183 | Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. *Circulation*, **2020**, 142, 1623-1632 | 16.7 | 20 |
| 182 | Two Tales: One Story: EMPEROR-Reduced and DAPA-HF. *Circulation*, **2020**, 142, 2201-2204 | 16.7 | 7 |
| 181 | Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. *Circulation*, **2020**, 142, 1205-1218 | 16.7 | 16 |
| 180 | Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). *European Heart Journal*, **2020**, 41, 3402-3418 | 9.5 | 40 |
| 179 | Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. *JAMA Network Open*, **2020**, 3, e203032 | 13.4 | 3 |
| 178 | Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. *Circulation*, **2020**, 141, e779-e806 | 16.7 | 58 |
| 177 | Cardiac Autoimmunity Is Associated With Subclinical Myocardial Dysfunction in Patients With Type 1 Diabetes Mellitus. *Circulation*, **2020**, 141, 1107-1109 | 16.7 | 5 |

| | | | |
|---|---|---|---|
| 176 | Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. *American Journal of Nephrology*, **2019**, 50, 473-480 | 4.6 | 17 |
| 175 | Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet, The*, **2019**, 394, 1169-1180 | 40 | 106 |
| 174 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *New England Journal of Medicine*, **2019**, 381, 1995-2008 | 59.2 | 2021 |
| 173 | Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. *Circulation*, **2019**, 140, 1463-1476 | 16.7 | 163 |
| 172 | Response by Nassif and Kosiborod to Letter Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes". *Circulation*, **2019**, 139, 305-306 | 16.7 | |
| 171 | Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2349-2353 | 6.7 | 7 |
| 170 | Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. *Circulation*, **2019**, 140, e294-e324 | 16.7 | 168 |
| 169 | Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. *Circulation*, **2019**, 140, 618-620 | 16.7 | 46 |
| 168 | Understanding Contemporary Use of Thiazolidinediones. *Circulation: Heart Failure*, **2019**, 12, e005855 | 7.6 | 19 |
| 167 | Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. *Journal of Cardiac Failure*, **2019**, 25, 584-619 | 3.3 | 30 |
| 166 | Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 798-809 | 6.9 | 64 |
| 165 | Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. *Diabetes, Obesity and Metabolism*, **2019**, 21 Suppl 2, 19-23 | 6.7 | 16 |
| 164 | A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). *European Journal of Heart Failure*, **2019**, 21, 665-675 | 12.3 | 145 |
| 163 | New frontiers for management of hyperkalaemia: the emergence of novel agents. *European Heart Journal Supplements*, **2019**, 21, A34-A40 | 1.5 | 3 |
| 162 | Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. *Diabetes Research and Clinical Practice*, **2019**, 151, 20-32 | 7.4 | 31 |
| 161 | Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1985-1989 | 6.7 | 11 |
| 160 | Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. *Diabetes, Obesity and Metabolism*, **2019**, 21, 261-266 | 6.7 | 6 |
| 159 | Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry. *Diabetes, Obesity and Metabolism*, **2019**, 21, 393-396 | 6.7 | 0 |

| | | | |
|---|---|---|---|
| 158 | Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2474-2485 | 6.7 | 19 |
| 157 | The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. *European Journal of Heart Failure*, **2019**, 21, 1402-1411 | 12.3 | 103 |
| 156 | Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. *Journal of the American College of Cardiology*, **2019**, 74, 1926-1942 | 15.1 | 19 |
| 155 | A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. *American Journal of Medicine*, **2019**, 132, S13-S20 | 2.4 | 1 |
| 154 | A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. *American Journal of Cardiology*, **2019**, 124 Suppl 1, S12-S19 | 3 | 8 |
| 153 | Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. *Circulation*, **2019**, 140, 2108-2118 | 16.7 | 13 |
| 152 | Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1121-1127 | 6.7 | 25 |
| 151 | Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. *Circulation*, **2019**, 139, 730-743 | 16.7 | 39 |
| 150 | Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". *Circulation*, **2018**, 137, 989-991 | 16.7 | 6 |
| 149 | Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2000-2003 | 6.7 | 20 |
| 148 | Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. *Journal of the American Geriatrics Society*, **2018**, 66, 1190-1194 | 5.6 | 34 |
| 147 | Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1419-1426 | 6.7 | 22 |
| 146 | Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1337-1341 | 6.7 | 39 |
| 145 | Hyperglycemia in Acute Coronary Syndromes: From Mechanisms to Prognostic Implications. *Endocrinology and Metabolism Clinics of North America*, **2018**, 47, 185-202 | 5.5 | 13 |
| 144 | Effect of glucose-lowering therapies on heart failure. *Nature Reviews Cardiology*, **2018**, 15, 282-291 | 14.8 | 34 |
| 143 | Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. *Kidney International*, **2018**, 94, 26-39 | 9.9 | 160 |
| 142 | Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. *Journal of the American College of Cardiology*, **2018**, 71, 2628-2639 | 15.1 | 263 |
| 141 | Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1983-1987 | 6.7 | 55 |

| | | | |
|---|---|---|---|
| 140 | Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. *European Heart Journal*, **2018**, 39, 193-200 | 9.5 | 3 |
| 139 | Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. *Diabetes, Obesity and Metabolism*, **2018**, 20, 763-765 | 6.7 | |
| 138 | Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. *Diabetes, Obesity and Metabolism*, **2018**, 20, 667-671 | 6.7 | 78 |
| 137 | Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). *Journal of Diabetes and Its Complications*, **2018**, 32, 1035-1039 | 3.2 | 2 |
| 136 | Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. *Diabetes, Obesity and Metabolism*, **2018**, 20, 389-399 | 6.7 | 31 |
| 135 | 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *Journal of the American College of Cardiology*, **2018**, 72, 3200-3223 | 15.1 | 180 |
| 134 | Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study. *Journal of Emergency Medicine*, **2018**, 55, 741-750 | 1.5 | 26 |
| 133 | Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). *Cardiovascular Diabetology*, **2018**, 17, 150 | 8.7 | 73 |
| 132 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet, The*, **2018**, 392, 1519-1529 | 40 | 771 |
| 131 | Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. *Circulation*, **2018**, 138, 1904-1907 | 16.7 | 75 |
| 130 | SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. *Journal of the American College of Cardiology*, **2018**, 71, 2497-2506 | 15.1 | 68 |
| 129 | Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. *Diabetes Care*, **2018**, 41, e106-e108 | 14.6 | 8 |
| 128 | Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). *American Heart Journal*, **2018**, 203, 25-29 | 4.9 | 15 |
| 127 | Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes. *Circulation*, **2018**, 138, 4-6 | 16.7 | 11 |
| 126 | Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. *Journal of Diabetes and Its Complications*, **2017**, 31, 1215-1221 | 3.2 | 25 |
| 125 | Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. *Journal of Diabetes and Its Complications*, **2017**, 31, 1188-1196 | 3.2 | 37 |
| 124 | Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). *Circulation*, **2017**, 136, 249-259 | 16.7 | 519 |
| 123 | Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. *Journal of General Internal Medicine*, **2017**, 32, 1044-1051 | 4 | 17 |

| | | | |
|---|---|---|---|
| 122 | Serum Magnesium Levels and In-Hospital Mortality in Acute Myocardial Infarction. *Journal of the American College of Cardiology*, **2017**, 69, 2771-2772 | 15.1 | 13 |
| 121 | THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. *Endocrine Practice*, **2017**, 23, 363-371 | 3.2 | 3 |
| 120 | Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 799-807 | 18.1 | 38 |
| 119 | Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10, | 5.8 | 6 |
| 118 | Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. *Journal of the American Heart Association*, **2017**, 6, | 6 | 14 |
| 117 | Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. *European Journal of Preventive Cardiology*, **2017**, 24, 1637-1645 | 3.9 | 73 |
| 116 | Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular DiseaseCVD Real Study. *Canadian Journal of Diabetes*, **2017**, 41, S51-S52 | 2.1 | 2 |
| 115 | Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Diabetes: Insights From the OPEN CTO Registry. *JACC: Cardiovascular Interventions*, **2017**, 10, 2174-2181 | 5 | 18 |
| 114 | Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. *Annals of Internal Medicine*, **2017**, 167, 73-74 | 8 | |
| 113 | Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. *Journal of Diabetes and Its Complications*, **2017**, 31, 1451-1457 | 3.2 | 2 |
| 112 | Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. *American Heart Journal*, **2017**, 189, 158-166 | 4.9 | 27 |
| 111 | Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction. *JAMA Cardiology*, **2017**, 2, 36-44 | 16.2 | 21 |
| 110 | Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 517-519 | 3.2 | 6 |
| 109 | Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. *American Heart Journal*, **2017**, 184, 114-120 | 4.9 | 33 |
| 108 | Gender differences in the association between discharge hemoglobin and 12-month mortality after acute myocardial infarction. *Clinical Cardiology*, **2017**, 40, 1279-1284 | 3.3 | 3 |
| 107 | Study design of Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): a multicenter, prospective, observational study. *Clinical and Experimental Emergency Medicine*, **2017**, 4, 154-159 | 1.7 | 4 |
| 106 | Potential New Agents for the Management of Hyperkalemia. *American Journal of Cardiovascular Drugs*, **2016**, 16, 19-31 | 4 | 12 |
| 105 | Predictors of Physician Under-Recognition of Angina in Outpatients With Stable Coronary Artery Disease. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, 554-9 | 5.8 | 35 |

| | | | |
|---|---|---|---|
| 104 | Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. *Journal of the American College of Cardiology*, **2016**, 68, 1368-9 | 15.1 | 34 |
| 103 | Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*, **2016**, 134, e535-e578 | 16.7 | 164 |
| 102 | Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. *Diabetes Care*, **2016**, 39, e99-e101 | 14.6 | 23 |
| 101 | Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, 372-9 | 5.8 | 17 |
| 100 | Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes. *Journal of Diabetes Science and Technology*, **2016**, 10, 1006-14 | 4.1 | 7 |
| 99 | High hemoglobin A1c variability is associated with early risk of microalbuminuria in children with T1D. *Pediatric Diabetes*, **2016**, 17, 398-406 | 3.6 | 9 |
| 98 | Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 567-73 | 5.5 | 14 |
| 97 | The Association Between Complementary and Alternative Medicine and Health Status Following Acute Myocardial Infarction. *Clinical Cardiology*, **2016**, 39, 440-5 | 3.3 | 2 |
| 96 | New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. *International Journal of Cardiology*, **2016**, 216, 46-51 | 3.2 | 19 |
| 95 | Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. *American Journal of Medicine*, **2016**, 129, 858-65 | 2.4 | 27 |
| 94 | Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Circulation: Cardiovascular Quality* | 5.8 | 33 |
| 93 | Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. *Pharmacological Research*, **2016**, 113, 585-591 | 10.2 | 72 |
| 92 | Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. *American Heart Journal*, **2016**, 182, 111-118 | 4.9 | 9 |
| 91 | Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. *American Heart Journal*, **2015**, 170, 753-759.e2 | 4.9 | 5 |
| 90 | Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. *Journal of the American Heart Association*, **2015**, 4, e002009 | 6 | 1 |
| 89 | Recognition of incident diabetes mellitus during an acute myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes*, **2015**, 8, 260-7 | 5.8 | 13 |
| 88 | Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. *New England Journal of Medicine*, **2015**, 372, 1577-8 | 59.2 | 40 |
| 87 | Excess Mortality among Persons with Type 2 Diabetes. *New England Journal of Medicine*, **2015**, 373, 1720-32 | 59.2 | 562 |

| | | | |
|---|---|---|---|
| 86 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Circulation*, **2015**, 132, 691-718 | 16.7 | 239 |
| 85 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care*, **2015**, 38, 1777-803 | 14.6 | 271 |
| 84 | Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 876-85 | 18.1 | 48 |
| 83 | Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *European Journal of Heart Failure*, **2015**, 17, 1050-6 | 12.3 | 98 |
| 82 | Use of an Intravascular Fluorescent Continuous Glucose Sensor in ICU Patients. *Journal of Diabetes Science and Technology*, **2015**, 9, 762-70 | 4.1 | 14 |
| 81 | Glucose management in critically ill adults and children. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 723-33 | 18.1 | 43 |
| 80 | Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. *European Journal of Preventive Cardiology*, **2015**, 22, 779-87 | 3.9 | 9 |
| 79 | Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. *American Journal of Cardiology*, **2014**, 113, 1267-72 | 3 | 9 |
| 78 | Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC: Cardiovascular Interventions*, **2014**, 7, 1-9 | 5 | 315 |
| 77 | Glycemic control and excess mortality in type 1 diabetes. *New England Journal of Medicine*, **2014**, 371, 1972-82 | 59.2 | 513 |
| 76 | Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. *Circulation*, **2014**, 129, 1303-9 | 16.7 | 50 |
| 75 | Reply: In regard to the TERISA trial. *Journal of the American College of Cardiology*, **2014**, 64, 420-1 | 15.1 | 1 |
| 74 | Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). *Circulation: Cardiovascular Quality and Outcomes*, **2014**, 7, 236-43 | 5.8 | 6 |
| 73 | Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. *American Heart Journal*, **2014**, 168, 457-465.e2 | 4.9 | 11 |
| 72 | Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. *Journal of the American College of Cardiology*, **2014**, 64, 811-9 | 15.1 | 30 |
| 71 | Performance of the Medtronic Sentrino continuous glucose management (CGM) system in the cardiac intensive care unit. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000037 | 4.5 | 29 |
| 70 | Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. *Circulation: Cardiovascular Quality and Outcomes*, **2014**, 7, 844-50 | 5.8 | 70 |
| 69 | The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000046 | 4.5 | 7 |

| | | | |
|---|---|---|---|
| 68 | Changes in low-density lipoprotein cholesterol levels after discharge for acute myocardial infarction in a real-world patient population. *American Journal of Epidemiology*, **2014**, 179, 1293-300 | 3.8 | 7 |
| 67 | Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000039 | 4.5 | 38 |
| 66 | Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina. *JAMA Internal Medicine*, **2014**, 174, 1403-5 | 11.5 | 13 |
| 65 | Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2223-33 | 27.4 | 222 |
| 64 | Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. *Journal of the American Heart Association*, **2014**, 3, e001380 | 6 | 114 |
| 63 | Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the veterans administration cardiac care follow-up clinical study. *Diabetes Care*, **2014**, 37, 409-18 | 14.6 | 21 |
| 62 | Variation in the incidence of hospital-acquired anemia during hospitalization with acute myocardial infarction (data from 57 US hospitals). *American Journal of Cardiology*, **2014**, 113, 1130-6 | 3 | 6 |
| 61 | Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. *Reviews in Cardiovascular Medicine*, **2014**, 15, 11-23 | 3.9 | 42 |
| 60 | Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States. *American Heart Journal*, **2013**, 166, 315-324.e1 | 4.9 | 2 |
| 59 | Advances in CKD detection and determination of prognosis: executive summary of the National Kidney Foundation-Kidney Early Evaluation Program (KEEP) 2012 annual data report. *American Journal of Kidney Diseases*, **2013**, 61, S1-3 | 7.4 | 12 |
| 58 | The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). *American Journal of Kidney Diseases*, **2013**, 61, S12-23 | 7.4 | 51 |
| 57 | Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. *Journal of the American College of Cardiology*, **2013**, 61, 2130-8 | 15.1 | 58 |
| 56 | The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction. *Journal of the American College of Cardiology*, **2013**, 62, 704-8 | 15.1 | 12 |
| 55 | Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). *Journal of the American College of Cardiology*, **2013**, 61, 2038-45 | 15.1 | 150 |
| 54 | Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. *Endocrine Practice*, **2013**, 19, 81-90 | 3.2 | 41 |
| 53 | Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 16-38 | 5.6 | 737 |
| 52 | Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. *Thrombosis Research*, **2012**, 129, 32-5 | 8.2 | 54 |
| 51 | Red blood cell indices and development of hospital-acquired anemia during acute myocardial infarction. *American Journal of Cardiology*, **2012**, 109, 1104-10 | 3 | 10 |

| | | | |
|---|---|---|---|
| 50 | Serum potassium levels and mortality in acute myocardial infarction. *JAMA - Journal of the American Medical Association*, **2012**, 307, 157-64 | 27.4 | 223 |
| 49 | Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction. *Diabetes Care*, **2012**, 35, 991-3 | 14.6 | 19 |
| 48 | Glucose variability and mortality in patients hospitalized with acute myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes*, **2012**, 5, 550-7 | 5.8 | 30 |
| 47 | Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial. *Diabetes Care*, **2012**, 35, 19-24 | 14.6 | 12 |
| 46 | Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the national registry of myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes* , **2012**, 5, 791-7 | 5.8 | 34 |
| 45 | Recovery from hospital-acquired anemia after acute myocardial infarction and effect on outcomes. *American Journal of Cardiology*, **2011**, 108, 949-54 | 3 | 17 |
| 44 | Hypoglycemia and adverse outcomes: marker or mediator?. *Reviews in Cardiovascular Medicine*, **2011**, 12, 132-5 | 3.9 | 14 |
| 43 | Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes*, **2010**, 3, 337-46 | 5.8 | 64 |
| 42 | Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. *Circulation: Cardiovascular Quality and Outcomes*, **2010**, 3, 236-42 | 5.8 | 27 |
| 41 | Glucose-lowering targets for patients with cardiovascular disease: focus on inpatient management of patients with acute coronary syndromes. *Circulation*, **2010**, 122, 2736-44 | 16.7 | 27 |
| 40 | Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. *JAMA - Journal of the American Medical Association*, **2010**, 303, 2141-7 | 27.4 | 485 |
| 39 | Outcomes associated with anemia in patients with heart failure. *Heart Failure Clinics*, **2010**, 6, 359-72 | 3.3 | 14 |
| 38 | Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. *Journal of the American College of Cardiology*, **2010**, 55, 1433-40 | 15.1 | 71 |
| 37 | Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. *American Heart Journal*, **2010**, 159, 81-9 | 4.9 | 19 |
| 36 | Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus. *American Journal of Cardiology*, **2010**, 105, 1090-4 | 3 | 15 |
| 35 | Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. *Circulation*, **2009**, 119, 1899-907 | 16.7 | 97 |
| 34 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Diabetes Care*, **2009**, 32, 187-92 | 14.6 | 500 |
| 33 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Circulation*, **2009**, 119, 351-7 | 16.7 | 265 |

| | | | |
|---|---|---|---|
| 32 | Glucose normalization and outcomes in patients with acute myocardial infarction. *Archives of Internal Medicine*, **2009**, 169, 438-46 | | 88 |
| 31 | Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *JAMA - Journal of the American Medical Association*, **2009**, 301, 1556-64 | 27.4 | 246 |
| 30 | An overview of glycemic control in the coronary care unit with recommendations for clinical management. *Journal of Diabetes Science and Technology*, **2009**, 3, 1342-51 | 4.1 | 11 |
| 29 | Training programs in outcomes research: the "field guide" for current opportunities. *Circulation: Cardiovascular Quality and Outcomes*, **2009**, 2, 678-80 | 5.8 | |
| 28 | Careers in cardiovascular outcomes research. *Circulation*, **2009**, 120, 76-81 | 16.7 | 5 |
| 27 | Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction. *American Journal of Cardiology*, **2009**, 103, 17-21 | 3 | 17 |
| 26 | Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. *American Journal of Cardiology*, **2009**, 104, 910-6 | 3 | 16 |
| 25 | Association of door-to-balloon time and mortality in patients > or =65 years with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *American Journal of Cardiology*, **2009**, 104, 1198-203 | 3 | 43 |
| 24 | Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. *Value in Health*, **2009**, 12, 185-7 | 3.3 | 77 |
| 23 | Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the | 15.1 | 272 |
| 22 | ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the | 15.1 | 152 |
| 21 | The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. *Journal of Cardiac Failure*, **2008**, 14, 27-34 | 3.3 | 12 |
| 20 | Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation*, **2008**, 117, 1018-27 | 16.7 | 290 |
| 19 | Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*, **2008**, 117, 1610-9 | 16.7 | 308 |
| 18 | Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. *Circulation*, **2008**, 118, 2139-45 | 16.7 | 86 |
| 17 | ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for | 16.7 | 167 |
| 16 | Hospital-wide code rates and mortality before and after implementation of a rapid response team. *JAMA - Journal of the American Medical Association*, **2008**, 300, 2506-13 | 27.4 | 230 |
| 15 | Blood glucose and its prognostic implications in patients hospitalised with acute myocardial infarction. *Diabetes and Vascular Disease Research*, **2008**, 5, 269-75 | 3.3 | 27 |

| | | | |
|---|---|---|---|
| 14 | Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. *American Journal of Cardiology*, **2007**, 99, 930-3 | 3 | 21 |
| 13 | Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. *Circulation*, **2007**, 115, 1975-81 | 16.7 | 114 |
| 12 | Changes in outcomes for internal medicine inpatients after work-hour regulations. *Annals of Internal Medicine*, **2007**, 147, 97-103 | 8 | 69 |
| 11 | Predictors of weight change in overweight patients with myocardial infarction. *American Heart Journal*, **2007**, 154, 711-7 | 4.9 | 30 |
| 10 | Usefulness of myocardial contrast echocardiography in predicting late mortality in patients with anterior wall acute myocardial infarction. *American Journal of Cardiology*, **2006**, 98, 1150-5 | 3 | 26 |
| 9 | Admission body temperature and mortality in elderly patients hospitalized for heart failure. *Journal of the American College of Cardiology*, **2006**, 47, 2563-4 | 15.1 | 18 |
| 8 | Relation of anemia at discharge to survival after acute coronary syndromes. *American Journal of Cardiology*, **2005**, 96, 496-9 | 3 | 38 |
| 7 | Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. *Archives of Internal Medicine*, **2005**, 165, 2237-44 | | 95 |
| 6 | Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. *Diabetes Care*, **2005**, 28, 1680-9 | 14.6 | 77 |
| 5 | Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. *Circulation*, **2005**, 111, 3078-86 | 16.7 | 472 |
| 4 | Assessment of right ventricular morphology and function. *Seminars in Respiratory and Critical Care Medicine*, **2003**, 24, 245-62 | 3.9 | 17 |
| 3 | Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. *Journal of Cardiac Failure*, **2003**, 9, 13-25 | 3.3 | 279 |
| 2 | The prognostic importance of anemia in patients with heart failure. *American Journal of Medicine*, **2003**, 114, 112-9 | 2.4 | 221 |
| 1 | Serum complement activation in congestive heart failure. *American Heart Journal*, **2001**, 141, 684-90 | 4.9 | 40 |